Company Name Aviir
Mailing Address 2463 Faber Place Palo Alto, CA 94303
Company Description Aviir is a venture-funded biotechnology company developing cutting-edge, convenient diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology draws on years of research at Stanford University, and combines the scientific founders’ deep understanding of disease marker proteins and advanced biostatistics. Aviir is pursuing an aggressive commercialization strategy, with initial products expected to reach the market in 2008.
Proceeds Purposes The proceeds will be used to fund commercialization of TruRisk(TM), Aviir’s proprietary cardiac risk assessment technology, and additional molecular testing services provided through Aviir Heart Laboratories, based in Irvine, California.